{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T13:55:50Z","timestamp":1726235750046},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,8,25]],"date-time":"2010-08-25T00:00:00Z","timestamp":1282694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s11912-010-0125-0","type":"journal-article","created":{"date-parts":[[2010,8,24]],"date-time":"2010-08-24T04:58:25Z","timestamp":1282625905000},"page":"374-382","source":"Crossref","is-referenced-by-count":8,"title":["Should Eligible Patients with T-Cell Lymphoma Receive High-Dose Therapy and Autologous Stem Cell Transplant in the Upfront Setting?"],"prefix":"10.1007","volume":"12","author":[{"given":"Carla","family":"Casulo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,25]]},"reference":[{"key":"125_CR1","doi-asserted-by":"crossref","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood 1997, 89: 3909\u20133918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"125_CR2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdf033","volume":"13","author":"T R\u00fcdiger","year":"2002","unstructured":"R\u00fcdiger T, Weisenburger DD, Anderson JR, et al.: Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin\u2019s Lymphoma Classification Project. Ann Oncol 2002, 13:140\u2013149.","journal-title":"Ann Oncol"},{"key":"125_CR3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/1097-0142(1984)54:4<687::AID-CNCR2820540416>3.0.CO;2-G","volume":"54","author":"SH Swerdlow","year":"1984","unstructured":"Swerdlow SH, Habeshaw JA, Rohatiner AZ, et al.: Caribbean T cell lymphoma\/leukemia. Cancer 1984, 54:687\u2013696.","journal-title":"Cancer"},{"key":"125_CR4","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"JM Vose","year":"2008","unstructured":"\u2022\u2022 Vose JM, Armitage JO, Weisenburger D: International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008, 26:4124\u20134130. This study evaluates the largest cohort of 1314 cases of PTCL and NKTCL organized from 22 centers worldwide and generates conclusions regarding geographic incidence of TCL, response to chemotherapy, and impact of histologic subtype.","journal-title":"J Clin Oncol"},{"key":"125_CR5","unstructured":"Swerdlow S, Campo E, Harris N: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Edited by Swerdlow S, Campo E, Harris N. Lyon, France: International Agency for Research on Cancer; 2008:269\u2013317."},{"key":"125_CR6","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1200\/JCO.1989.7.12.1783","volume":"12","author":"JO Armitage","year":"1989","unstructured":"Armitage JO, Vose JM, Linder J, et al.: Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol 1989, 12:1783\u20131790","journal-title":"J Clin Oncol"},{"key":"125_CR7","first-page":"76","volume":"92","author":"C Gisselbrecht","year":"1998","unstructured":"Gisselbrecht C, Gaulard P, Lepage E, et al.: Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA). Blood 1998, 92:76\u201382.","journal-title":"Blood"},{"key":"125_CR8","doi-asserted-by":"crossref","unstructured":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987\u2013994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"125_CR9","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1200\/JCO.1997.15.6.2296","volume":"15","author":"SM Ansell","year":"1997","unstructured":"Ansell SM, Habermann TM, Kurtin PJ, et al.: Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 1997, 15:2296\u20132301.","journal-title":"J Clin Oncol"},{"key":"125_CR10","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R, et al.: Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004, 103:2474\u20132479.","journal-title":"Blood"},{"key":"125_CR11","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","volume":"115","author":"J Iqbal","year":"2010","unstructured":"Iqbal J, Weisenburger DD, Greiner TC, et al.: Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 2010, 115:1026\u20131036.","journal-title":"Blood"},{"key":"125_CR12","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","volume":"103","author":"MP Escalon","year":"2005","unstructured":"Escalon MP, Liu NS, Yang Y, et al.: Prognostic factors and treatment of patients with T cell NHL: the M.D. Anderson Cancer Center Experience. Cancer 2005, 103: 2091\u20132098.","journal-title":"Cancer"},{"key":"125_CR13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.annonc.a057673","volume":"1","author":"B Coiffier","year":"1990","unstructured":"Coiffier B, Brousse N, Peuchmaur, et al.: Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Ann Oncol 1990, 1:45\u201350.","journal-title":"Ann Oncol"},{"key":"125_CR14","doi-asserted-by":"crossref","unstructured":"AbouYabis A, Shenoy P, Flowers C, et al.: Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: a comprehensive meta-analysis [abstract 3452]. Presented at the American Society of Hematology Annual Meeting. December 2007.","DOI":"10.1182\/blood.V110.11.3452.3452"},{"key":"125_CR15","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","volume":"104","author":"E Marchi","year":"2005","unstructured":"Marchi E, Alinari L, Tani M, et al.: Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005, 104:2437\u20132444.","journal-title":"Cancer"},{"key":"125_CR16","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","volume":"21","author":"PL Zinzani","year":"2010","unstructured":"Zinzani PL, Venturini F, Stefoni V, et al.: Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 2010, 21:860\u2013863.","journal-title":"Ann Oncol"},{"key":"125_CR17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","volume":"92","author":"HT Arkenau","year":"2007","unstructured":"Arkenau HT, Chong G, Cunningham D, et al.: Gemcitabine, cisplatin, and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 2007, 92:271\u2013272.","journal-title":"Haematologica"},{"key":"125_CR18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-005-0136-y","volume":"58","author":"JG Kim","year":"2006","unstructured":"Kim JG, Sohn SK, Chae YS, et al.: CHOP plus etoposide and gemcitabine (CHOP-EG) as first line therapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 2006, 58:35\u201339.","journal-title":"Cancer Chemother Pharmacol"},{"key":"125_CR19","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med 1995, 333:1540\u20131545.","journal-title":"N Engl J Med"},{"key":"125_CR20","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2001.19.17.3766","volume":"19","author":"J Rodriguez","year":"2001","unstructured":"Rodriguez J, Munsell M, Yazji S, et al.: Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001, 19:3766\u20133770.","journal-title":"J Clin Oncol"},{"key":"125_CR21","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1046\/j.1365-2141.2003.04203.x","volume":"120","author":"KW Song","year":"2003","unstructured":"Song KW, Mollee P, Keating A, et al.: Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003, 120:978\u2013985.","journal-title":"Br J Haematol"},{"key":"125_CR22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","volume":"134","author":"T Kewalramani","year":"2006","unstructured":"Kewalramani T, Zelenetz AD, Teruya-Feldstein J, et al.: Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006, 134:202\u2013207.","journal-title":"Br J Haematol"},{"key":"125_CR23","doi-asserted-by":"crossref","unstructured":"Horwitz S, Moskowitz C, Kewalramani T, et al.: Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed\/refractory peripheral T-cell lymphomas: minimal benefit when analyzed by intent to treat [abstract 2679]. Presented at the American Society of Hematology Annual Meeting. 2005.","DOI":"10.1182\/blood.V106.11.2679.2679"},{"key":"125_CR24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.bmt.1705712","volume":"40","author":"S Smith","year":"2007","unstructured":"Smith S, Bolwell B, Rybicki L, et al.: Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant 2007, 40:239\u2013243.","journal-title":"Bone Marrow Transplant"},{"key":"125_CR25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.bmt.1702867","volume":"27","author":"AK Blystad","year":"2001","unstructured":"Blystad AK, Enblad G, Kvaloy S, et al.: High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001, 27:711\u2013716.","journal-title":"Bone Marrow Transplant"},{"key":"125_CR26","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","volume":"14","author":"J Rodriguez","year":"2003","unstructured":"Rodriguez J, Caballero MD, Gutierrez A, et al.: High-dose chemotherapy and autologous stem cell transplantation in peripheral T cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003, 14:1768\u20131775.","journal-title":"Ann Oncol"},{"key":"125_CR27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1704367","volume":"33","author":"E Jantunen","year":"2004","unstructured":"Jantunen E, Wiklund T, Juvonen E, et al.: Autologous stem cell transplantation in adult patients with peripheral T cell lymphoma: a nationwide survey. Bone Marrow Transplant 2004, 33:405\u2013410.","journal-title":"Bone Marrow Transplant"},{"key":"125_CR28","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/annonc\/mdl466","volume":"18","author":"J Rodriguez","year":"2007","unstructured":"Rodriguez J, Conde E, Gutierrez A, et al.: The results of consolidation with autologous stem-cell transplantation in patients with peripheral T cell lymphoma in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007, 18:652\u2013657.","journal-title":"Ann Oncol"},{"key":"125_CR29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bmt.1705752","volume":"40","author":"S Feyler","year":"2007","unstructured":"Feyler S, Prince HM, Pearce R, et al.: The role of high dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007, 40:443\u2013450.","journal-title":"Bone Marrow Transplant"},{"key":"125_CR30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bbmt.2008.11.010","volume":"15","author":"DH Yang","year":"2009","unstructured":"Yang DH, Kim WS, Kim SJ, et al.: Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol Blood Marrow Transplant 2009, 15:118\u2013125.","journal-title":"Biol Blood Marrow Transplant"},{"key":"125_CR31","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2000.18.16.3025","volume":"18","author":"C Haioun","year":"2000","unstructured":"Haioun C, Lepage E, Gisselbrecht C, et al.: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin\u2019s lymphoma: final analysis of the prospective LNH87-2 protocol\u2014A Group d\u2019Etude des Lymphomes de l\u2019Adulte study. J Clin Oncol 2000, 18:3025\u20133030.","journal-title":"J Clin Oncol"},{"key":"125_CR32","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2002.02.125","volume":"20","author":"C Gisselbrecht","year":"2002","unstructured":"Gisselbrecht C, Lepage E, Molina T, et al.: Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002, 20:2472\u20132479.","journal-title":"J Clin Oncol"},{"key":"125_CR33","unstructured":"\u2022\u2022 d\u2019Amore F, Relander T, Lauritzen G, et al.: Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral T cell lymphomas (PTCLs)\u2014overall and subtype specific results of a phase II study from the Nordic Lymphoma Group [abstract 53]. Presented at the Annual Meeting of the European Hematology Association. Berlin, Germany; 2009. This is the largest PTCL-specific prospective study of upfront ASCT in PTCL after first complete or partial remission."},{"key":"125_CR34","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","volume":"20","author":"C Corradini","year":"2006","unstructured":"Corradini C, Tarella C, Zallio F, et al.: Long-term follow up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006, 20:1533\u20131538.","journal-title":"Leukemia"},{"key":"125_CR35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","volume":"79","author":"J Rodriguez","year":"2007","unstructured":"Rodriguez J, Conde E, Gutierrez A, et al.: Front-line autologous stem-cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the GEL-TAMO Study Group. Eur J Hematol 2007, 79:32\u201338.","journal-title":"Eur J Hematol"},{"key":"125_CR36","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","volume":"19","author":"S Mercadal","year":"2008","unstructured":"Mercadal S, Briones J, Xicoy B, et al.: Intensive chemotherapy (high dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008, 19:958\u2013963.","journal-title":"Ann Oncol"},{"key":"125_CR37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2008","unstructured":"\u2022\u2022 Reimer P, Rudiger T, Gessinger E, et al.: Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2008, 27:106\u2013113. This is the second largest PTCL-specific prospective study of upfront ASCT in PTCL after first complete or partial remission.","journal-title":"J Clin Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-010-0125-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-010-0125-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-010-0125-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T21:22:11Z","timestamp":1591824131000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-010-0125-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,25]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["125"],"URL":"https:\/\/doi.org\/10.1007\/s11912-010-0125-0","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,25]]}}}